Previous 10 | Next 10 |
home / stock / vktx / vktx articles
On Tuesday, the U.S. indices exhibited a varied performance, as the S&P 500 rose by nearly 0.2% to reach 5,078.18, while the Dow Jones Industri...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to ...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported fourth-quarter 2023 sales of $28.1 million, beating the consensus of $25.72 mi...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,915...
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) ...
Tuesday, Viking Therapeutics Inc (NASDAQ:VKTX) released top-line results from its Phase 2 trial of VK2735, a dual agonist of the glucagon...
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow...
The Nasdaq 100 closed higher by 1% on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be ...
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minera...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-15 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 05:42:00 ET Viking Therapeutics (NASDAQ: VKTX) has been one of the hottest healthcare stocks to own this year, thanks to hype and excitement relating to its promising weight loss treatment, VK2735. The potential that investors see in the drug is a key reason the stock h...
2024-07-10 06:41:00 ET Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for obesity like Wegovy and Zepbound. Both companies ha...